cancer
Conditions
Interventions
Intervention Group:Different doses RP903
Sponsors
Fudan University ShangHai Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Understand and voluntarily sign the informed consent; 2. Aged 18-75 (including 18 and 75), male and female; 3. You can swallow the whole pill;
Exclusion criteria
Exclusion criteria: 1. Patients with known allergies to RP903 components and patients with known allergies to fulvestrant are not able to enroll in phase Ib extended cohort 4 (breast cancer cohort); 2. Previous treatment with PI3K, mTOR or AKT inhibitors; 3. Participate in other clinical studies, unless observational (non-interventional), within 4 weeks before the first dose Follow-up period for bed study or intervention study; 4. Underwent major surgery or was in recovery from surgery or expected to be in research within 4 weeks before the first dose Major surgery during the study period;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics; | — |
Countries
China
Contacts
Public ContactJian Zhang/XiChun Hu
Fudan University ShangHai Cancer Hospital
Outcome results
None listed